- Download App
Cancer type > Hematological Cancers
Definition of Pediatric lymphoma
Pediatric lymphoma is a type of cancer that originates in the lymphatic system, which is part of the body’s immune system. It occurs when lymphocytes (a type of white blood cell) grow uncontrollably, forming tumors in lymph nodes or other parts of the body such as the spleen, bone marrow, or other organs.
There are two main types of pediatric lymphoma:
Hodgkin Lymphoma (HL):
Characterized by the presence of Reed-Sternberg cells (a specific type of abnormal lymphocyte).
It often starts in lymph nodes in the neck, chest, or underarms.
Common in adolescents and older children.
Non-Hodgkin Lymphoma (NHL):
A diverse group of lymphomas that do not involve Reed-Sternberg cells.
More aggressive than Hodgkin lymphoma but often responds well to treatment.
Common in younger children.
Both types can cause symptoms such as swollen lymph nodes, fever, fatigue, and weight loss. Early diagnosis
SYMPTOMS OF PAEDIATRIC LYMPHOMAS
Symptoms of Pediatric Lymphomas
The symptoms of pediatric lymphomas can vary depending on the type (Hodgkin or Non-Hodgkin), location, and extent of the disease. Many symptoms overlap with other illnesses, so proper medical evaluation is essential.
General Symptoms
Fever: Persistent or recurrent fevers, often without a known infection.
Night Sweats: Drenching sweats, especially during sleep.
Unexplained Weight Loss: Significant weight loss without dietary changes or exercise.
Fatigue and Weakness: Due to the body’s immune system being compromised.
Lymph Node Swelling
Painless Swelling: Enlarged lymph nodes, often in the neck, underarm, or groin.
Nodes may feel firm or rubbery and are typically not tender.
Symptoms Based on Lymphoma Location
Chest (Mediastinum)
Persistent Cough.
Shortness of Breath.
Chest Pain or Discomfort: Caused by enlarged lymph nodes pressing on the airway or nearby structures.
Abdomen
Swelling or Fullness: Due to enlarged lymph nodes or organs like the spleen or liver.
Abdominal Pain.
Nausea or Vomiting.
Bowel Obstruction: Rare but possible in advanced cases of Non-Hodgkin lymphoma.
Central Nervous System (Rare)
Headaches.
Seizures.
Difficulty Walking or Coordination Problems: If the lymphoma spreads to the brain or spinal cord.
Skin Changes
Itchy Skin (Pruritus): Common in Hodgkin lymphoma.
Rashes or Nodules: Rare but may occur if lymphoma spreads to the skin.
Signs of Low Blood Counts
Frequent Infections: Due to weakened immunity.
Bruising or Bleeding: If the bone marrow is affected, leading to low platelet levels.
Pale Skin: From anemia caused by reduced red blood cell production.
Other Symptoms
Bone Pain: If the lymphoma has spread to the bone marrow or bones.
Swollen Liver or Spleen: Can cause discomfort or a feeling of fullness.
Note:
Symptoms often mimic those of other common childhood illnesses, such as infections.
Persistent, unexplained, or worsening symptoms warrant prompt medical evaluation. Early diagnosis and treatment significantly improve outcomes.
Types of Pediatric Lymphoma
Pediatric lymphoma is broadly classified into two main categories: Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphoma (NHL). These are further divided into subtypes based on the characteristics of the cancer cells and the disease’s progression.
Hodgkin Lymphoma (HL)
Hodgkin lymphoma is less common than non-Hodgkin lymphoma in children but is more prevalent in adolescents. It is characterized by the presence of Reed-Sternberg cells, a specific type of abnormal lymphocyte.
Subtypes of Hodgkin Lymphoma
Nodular Sclerosis Hodgkin Lymphoma:
The most common subtype in children and adolescents.
Typically affects lymph nodes in the chest and neck.
Mixed Cellularity Hodgkin Lymphoma:
More common in younger children and those with weakened immune systems.
Often involves abdominal lymph nodes.
Lymphocyte-Rich Hodgkin Lymphoma:
A rare subtype with a high number of normal lymphocytes.
Lymphocyte-Depleted Hodgkin Lymphoma:
Extremely rare in children and associated with advanced disease.
Nodular Lymphocyte-Predominant Hodgkin Lymphoma:
A rare, slower-growing subtype of Hodgkin lymphoma.
Non-Hodgkin Lymphoma (NHL)
Non-Hodgkin lymphoma is more common in children under 15 and is generally more aggressive than Hodgkin lymphoma. It is classified based on the type of lymphocyte involved (B-cells or T-cells) and the growth pattern.
Subtypes of Non-Hodgkin Lymphoma
Burkitt Lymphoma:
A very aggressive type but highly treatable.
Commonly involves the abdomen, jaw, or central nervous system.
Associated with Epstein-Barr virus in some cases.
Diffuse Large B-Cell Lymphoma (DLBCL):
The most common subtype of NHL in children.
Can occur in lymph nodes, the chest, or other organs.
Lymphoblastic Lymphoma:
Often arises from T-cells and may present as a mass in the chest.
Closely related to acute lymphoblastic leukemia (ALL).
Anaplastic Large Cell Lymphoma (ALCL):
A rare subtype that originates from T-cells.
Frequently affects lymph nodes, skin, and sometimes the lungs or other organs.
Differences Between HL and NHL in Children
Feature | Hodgkin Lymphoma (HL) | Non-Hodgkin Lymphoma (NHL) |
|---|---|---|
Age Group | More common in adolescents | More common in younger children |
Growth Rate | Slow-growing | Often aggressive and fast-growing |
Common Symptoms | Enlarged lymph nodes in the neck or chest | Abdominal swelling, chest masses |
Treatment Response | Highly curable with standard treatment | Aggressive, but often treatable |
Other Rare Pediatric Lymphomas
Primary Mediastinal B-Cell Lymphoma:
A subtype of DLBCL often affecting the chest.
More common in older children and adolescents.
Extranodal NK/T-cell Lymphoma:
Rare and typically involves the nasal cavity or other extranodal sites.
Associated with Epstein-Barr virus.
Key Notes
The type of lymphoma determines the treatment approach and prognosis.
Hodgkin lymphoma generally has a higher survival rate, while some subtypes of NHL require intensive treatment but are also highly curable.
Early diagnosis and specialized care significantly improve outcomes for all types of pediatric lymphoma.
CAUSES AND RISK FACTORS OF PAEDIATRIC LYMPHOMAS
Causes and Risk Factors of Pediatric Lymphomas
The exact cause of pediatric lymphomas is not fully understood. However, lymphomas arise when genetic mutations cause lymphocytes (a type of white blood cell) to grow uncontrollably and fail to die at the appropriate time. These changes may be influenced by a combination of genetic, environmental, and immune system factors.
Causes
Genetic Mutations:
Mutations in genes regulating cell growth and division can lead to abnormal lymphocyte proliferation.
These mutations may occur spontaneously or be triggered by external factors.
Risk Factors
Immune System Deficiency
Inherited Immune Disorders:
Conditions like Wiskott-Aldrich syndrome, severe combined immunodeficiency (SCID), and ataxia-telangiectasia increase the risk of lymphoma.
Acquired Immune Suppression:
HIV/AIDS significantly raises the likelihood of developing lymphoma.
Post-organ transplant immunosuppressive therapy can also predispose children to lymphoma.
Infections
Certain infections are associated with an increased risk of pediatric lymphomas, particularly Non-Hodgkin Lymphoma (NHL):
Epstein-Barr Virus (EBV):
Strongly linked to Burkitt lymphoma and some Hodgkin lymphoma cases.
Helicobacter pylori:
Associated with gastric lymphoma.
Human Immunodeficiency Virus (HIV):
Suppresses the immune system, increasing the risk of lymphoma.
Family History and Genetics
A family history of lymphoma or other cancers may slightly increase the risk.
Genetic syndromes such as Li-Fraumeni syndrome or Down syndrome are associated with higher rates of childhood cancers, including lymphoma.
Environmental Exposures
Radiation Exposure:
High doses of ionizing radiation (e.g., from medical imaging or environmental sources) can increase the risk of cancer.
Chemical Exposure:
Prolonged exposure to pesticides, solvents, or industrial chemicals may elevate the risk.
Autoimmune Diseases
Conditions like lupus or rheumatoid arthritis may predispose children to lymphoma due to chronic immune system activation.
Age and Gender
Hodgkin Lymphoma (HL):
More common in adolescents and young adults.
Slightly more prevalent in males.
Non-Hodgkin Lymphoma (NHL):
More common in younger children, particularly boys.
Weakened Immune System
Children undergoing treatment for other cancers or receiving immunosuppressive drugs are at higher risk.
Key Points
While some risk factors, such as genetic conditions or immune deficiencies, cannot be controlled, avoiding unnecessary radiation exposure and managing infections can help reduce risks.
Many children with lymphoma have no identifiable risk factors, highlighting the importance of early detection and treatment regardless of predisposition.
Treatment of Pediatric Lymphomas
The treatment for pediatric lymphomas depends on the type of lymphoma (Hodgkin Lymphoma [HL] or Non-Hodgkin Lymphoma [NHL]), the stage of the disease, and the child’s overall health. The goal is to eliminate cancer cells while minimizing long-term side effects.
Treatment of Hodgkin Lymphoma (HL)
Hodgkin lymphoma in children is highly treatable, and most children achieve long-term remission.
Chemotherapy
The primary treatment for HL.
Administered in cycles, often over several months.
Commonly used regimens:
ABVD: Adriamycin, Bleomycin, Vinblastine, Dacarbazine.
OEPA/COPDAC: Used for younger children, with drugs like Vincristine, Prednisone, and Cyclophosphamide.
Radiation Therapy
Used for children with bulky or advanced disease or residual cancer after chemotherapy.
Delivered in low doses to minimize long-term side effects.
Targeted Therapy
Used in cases where standard treatments are ineffective or for relapsed disease.
Brentuximab Vedotin: Targets CD30-positive cells in HL.
Checkpoint Inhibitors: Pembrolizumab or nivolumab are immunotherapy options for relapsed/refractory HL.
Treatment of Non-Hodgkin Lymphoma (NHL)
Non-Hodgkin lymphoma in children is aggressive but often responds well to treatment.
Chemotherapy
The mainstay of NHL treatment.
Intensity and duration depend on the subtype and stage of NHL:
Burkitt Lymphoma: Requires high-dose, short-duration chemotherapy.
Diffuse Large B-Cell Lymphoma (DLBCL): Treated with chemotherapy similar to Burkitt lymphoma.
Lymphoblastic Lymphoma: Treated like acute lymphoblastic leukemia (ALL) with multi-phase chemotherapy.
Anaplastic Large Cell Lymphoma (ALCL): Requires targeted chemotherapy regimens.
Targeted Therapy
Rituximab: Used for B-cell NHL, targeting the CD20 protein on cancer cells.
Crizotinib: For ALK-positive anaplastic large cell lymphoma.
Radiation Therapy
Rarely used but may be considered for localized disease or to control tumors compressing vital organs.
CNS Prophylaxis
Prevents lymphoma from spreading to the brain or spinal cord.
Includes intrathecal chemotherapy (directly injected into the cerebrospinal fluid).
Stem Cell Transplant
Used for relapsed or refractory lymphomas after initial treatments.
Autologous Stem Cell Transplant: Uses the patient’s own stem cells.
Allogeneic Stem Cell Transplant: Uses donor stem cells, typically reserved for aggressive or recurrent cases.
Immunotherapy
Emerging treatment option, particularly for relapsed or refractory lymphomas:
CAR T-Cell Therapy: Engineered T-cells target lymphoma cells. Effective for certain B-cell lymphomas.
Monoclonal Antibodies: Directly target proteins on cancer cells.
Surgery
Rarely used in lymphoma but may be required to remove tumors causing obstruction or for diagnostic purposes.
Supportive Care
Infection Prevention: Antibiotics or antifungal medications during chemotherapy to prevent infections.
Nutritional Support: To maintain strength during treatment.
Psychological Support: Counseling for children and families to manage stress and emotional challenges.
Clinical Trials
Participation in clinical trials provides access to cutting-edge therapies, including novel drugs, immunotherapy, or targeted treatments.
Prognosis
Hodgkin Lymphoma: Survival rates exceed 90%, especially for early-stage disease.
Non-Hodgkin Lymphoma: Prognosis varies by subtype, but most children achieve long-term remission with appropriate treatment.
Long-Term Monitoring
Regular follow-ups to monitor for relapse and manage late side effects of treatment, such as growth issues, infertility, or secondary cancers.
Conclusion
Pediatric lymphomas are highly treatable, and advances in therapies continue to improve survival rates. A multidisciplinary approach ensures that children receive the most effective treatment with minimal long-term complications.
4o
Prevention of Pediatric Lymphoma
There is no guaranteed way to prevent pediatric lymphoma, as its exact causes are not fully understood and many risk factors (like genetic predispositions or immune system issues) cannot be controlled. However, some steps can be taken to minimize known risks and promote overall health.
Manage and Treat Underlying Medical Conditions
Address Immune Deficiencies:
Early diagnosis and management of inherited immune disorders (e.g., severe combined immunodeficiency, Wiskott-Aldrich syndrome) can reduce the risk of lymphoma.
Regular monitoring for children with known immune system issues is essential.
Treat Chronic Infections:
Conditions like HIV and Epstein-Barr virus (EBV) infections are associated with a higher risk of lymphoma.
Ensure timely treatment of such infections and manage them effectively.
Avoid Unnecessary Radiation Exposure
Limit Diagnostic Imaging:
Reduce the use of X-rays and CT scans in children unless medically necessary.
Follow Radiation Safety Guidelines:
Ensure appropriate protective measures when exposed to radiation, especially in medical or environmental settings.
Reduce Exposure to Environmental Toxins
Minimize Chemical Exposures:
Avoid prolonged exposure to pesticides, solvents, and other harmful chemicals.
Avoid Tobacco Smoke:
Secondhand smoke exposure can increase the risk of several childhood illnesses, including cancer.
Promote a Healthy Lifestyle
Balanced Diet:
Provide a diet rich in fruits, vegetables, and whole grains to strengthen the immune system.
Physical Activity:
Encourage regular exercise to maintain overall health.
Reduce Obesity:
Excess weight can affect immune function and overall health, although its direct link to pediatric lymphoma is unclear.
Genetic Counseling for High-Risk Families
Families with a history of genetic conditions or cancers should consider genetic counseling to assess risks and establish a monitoring plan.
Vaccination and Infection Prevention
HIV Prevention:
Practice safe behaviors to prevent HIV transmission, including maternal care during pregnancy to reduce the risk of vertical transmission.
Epstein-Barr Virus (EBV):
While a vaccine for EBV is not yet available, maintaining good hygiene practices can help reduce the risk of contracting this virus.
Hepatitis B Vaccine:
Protects against hepatitis-related immune system changes that could increase cancer risks.
Avoid Immunosuppressive Drugs if Possible
Immunosuppressive medications (e.g., after organ transplants) may increase lymphoma risk. Use only when necessary and monitor the child closely under medical guidance.
Early Monitoring for At-Risk Children
Children with genetic conditions (e.g., Down syndrome) or chronic immune suppression should undergo regular check-ups to detect any early signs of lymphoma.
Challenges in Prevention
Most cases of pediatric lymphoma are not linked to avoidable risk factors, and many children who develop lymphoma have no identifiable risks.
The focus should remain on early detection, prompt diagnosis, and effective treatment.
Conclusion
While pediatric lymphoma cannot always be prevented, reducing environmental exposures, managing infections and immune-related conditions, and promoting a healthy lifestyle can help lower potential risks. Families with high-risk children should work closely with healthcare providers for regular monitoring and preventive care.
NEWER ADVANCEMENTS/RESEARCHERS IN PAEDIATRIC CANCERS
Recent advancements in pediatric cancer research have led to significant improvements in diagnosis, treatment, and patient outcomes. Key developments include:
Precision Medicine and Genetic Profiling:
Whole Genome Sequencing: The NHS has implemented whole genome sequencing to expedite treatment for children with cancer. This approach sequences the entire genetic code of a patient’s tumor, identifying mutations that drive cancer development. In trials, it provided comprehensive insights within ten days, streamlining the diagnostic process.
Personalized Treatment Plans: Studies have shown that tailored treatments based on individual genetic profiles can significantly improve outcomes. For instance, personalized medicine has been found to shrink or stabilize tumors in 26% of cases, compared to 12% with standard care.
Immunotherapy and CAR T-Cell Therapy:
CAR T-Cell Therapy: This innovative treatment involves modifying a patient’s T-cells to target cancer cells. It has shown promise in treating pediatric cancers, including acute lymphoblastic leukemia.
Rapid Diagnostic Techniques:
AI-Powered MRI Analysis: Researchers have developed rapid tests that can diagnose brain cancers in children within 10 minutes using MRI scans and artificial intelligence. This method identifies metabolic markers unique to each tumor type, reducing the need for invasive biopsies and significantly shortening waiting times.
Advanced Drug Therapies:
Trametinib for Brain Cancer: An 11-year-old girl with a rare brain cancer experienced significant improvement after receiving Trametinib, a drug initially developed for melanoma. This case highlights the potential of repurposing existing drugs for pediatric cancers.
Lutathera Approval: The FDA approved Lutathera for pediatric patients aged 12 and older with specific neuroendocrine tumors, marking a significant step in expanding treatment options for young patients.
Collaborative Research Initiatives:
Children’s Oncology Group (COG): This NCI-funded network conducts clinical trials that have substantially improved treatment outcomes for children with cancer. COG’s efforts have led to increased cure rates for several childhood cancers.
Pediatric Cancer Genome Project: Launched in 2010, this project has sequenced the genomes of over 700 pediatric cancer patients, leading to discoveries that inform diagnostic and treatment strategies.
These advancements underscore the importance of continued research and collaboration in the fight against pediatric cancers, offering hope for improved survival rates and quality of life for young patients.